AR-12286 ophthalmic solution
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for AR-12286 ophthalmic solution, covering 2015-04-24 to 2015-04-24. Get the full timeline:
Most recent: Clinical Trial Update: A Prospective Study to Assess the Hypotensive Efficacy of Rho-Kinase Inhibitor AR-12286 Ophthalmic Solution 0.5% and 0.7% in Patients With Exfoliation Syndrome and Ocular Hypertension or Glaucoma [Phase 2]